EXPLORING THE INTERPLAY BETWEEN BUSINESS REGULATION & CORPORATE CONDUCT (BRCC) Rijit Sengupta Jaipur, 13 th April 2012.

Slides:



Advertisements
Similar presentations
Qualitative Study Initial Thinking Impact of Learning Environments on Well being of Children.
Advertisements

Policies and Procedures for Civil Society Participation in GEF Programme and Projects presented by GEF NGO Network ECW.
An Introduction to professional services. The professional services The professional services support businesses of all sizes across the economy, providing.
Project Advisory Committee Meeting 26th June 2012, New Delhi Vikash Batham CUTS International Exploring the Interplay between Business Regulation and Corporate.
Framework for Competition Reforms (FCR): Guiding Principles Rijit Sengupta CUTS International CREW International Conference 19 th Nov 2014, Bangkok.
Peter Tarfa Rio De Janeiro, Brazil 6-7 November 2008
Gunjan Organisation for Community Development. Goal: To stimulate better business to achieve sustainable development objectives in India Objectives: 
Brief Overview of the CREW Project Rijit Sengupta CUTS International CREW Project Inception Meeting March 2013, Jaipur (India)
1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.
Social Accounting and Audit (SAA) and the Social Audit Network An introduction…
EMS Auditing Definitions
Water Stewardship: a Vision on Sustainable Water Management in Agriculture “Water in the world” Lecture series, March 2 nd 2011 Rob D’hondt.
1 Regulatory Impact Assessment: Methodology and Best Practices David Shortall INMETRO International Workshop on Conformity Assessment Rio de Janeiro, Brazil.
Dr Dominique Allwood Public Health Registrar
Facilitated by Goldengate Consulting July Introduction Corporate Social Responsibility.
Rethinking Business Responsibility In India: a review of Pharmaceutical & Private Healthcare sectors Vikash Batham, CUTS International Developing an Inclusive.
Eurasian Corporate Governance Roundtable
The Knowledge Resources Guide The SUVOT Project Sustainable and Vocational Tourism Rimini, 20 October 2005.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Beirut – 20 April 2011 Citizens as partners: current issues and challenges Charles-Henri Montin Senior Regulatory Adviser Ministère de l’économie et des.
TRENDS AND CONSUMERISM IN HEALTH CARE Important Attributes Of Quality Health Care: Consumer Perspectives.
Project Launch Meeting National Competition Policy and Economic Growth in India - ComPEG Presentation on Project Overview Natasha Nayak, CUTS.
WELCOME RDC/ CUTS/ BRCC-Gujarat : Promoting Responsible Business in Pharmaceuticals and Private Healthcare Sector STATE LEVEL STAKEHOLDER DIALOGUE.
Performance Measurement and Analysis for Health Organizations
Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.
A forward looking agenda on CSR in India – a CSO perspective Rijit Sengupta CUTS Global Summit on CSR & Transparency Delhi, 8-9 July, 2011.
Joint Venture in construction company in West Bank.
Collusive behaviour in Healthcare and impact on consumers: evidences from Assam and Chhattisgarh Rijit Sengupta CUTS International COHED National Policy.
Country Summary for Ukraine (part 1) status for Roman Volosyanchuk, IUCN CPC.
Assessing The Policy Outputs Environment for Effective Programming Mohammed M Tumala (MEMS) Theresa Effa Kaka (ENHANSE) Chinelo Ezeobi (COMPASS)
Collusion among Health Service Providers in India Need for Regulatory Enforcement PRESENTATION ON BACKGROUND AND DRAFT PROJECT METHODOLOGY.
Introduction to Prescription Analysis & Methodology
 What is Public Relations Research? Research is important and thus it is the key to a successful Public Relations programme. Research assists in gathering.
WHO and the Global Fund harmonized tool for Pharmaceutical Country Profiles Richard Laing & Enrico Cinnella, November 2011.
Critical Dimensions of Indian Investments in Africa (The IIA Project) 01 st PAC MEETING Vikash Batham 16th April, 2014, New Delhi.
National Competition Policy and Economic Growth in India (ComPEG Project) July 2012 – December 2013 Terms of Reference for Sector Studies.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Promoting Drug and Therapeutics Committees in the Developing World
National Policy Forum 8th October 2012, New Delhi Exploring the Interplay between Business Regulation and Corporate Conduct in India (BRCC Project) Project.
Indicators to Measure Progress and Performance IWRM Training Course for the Mekong July 20-31, 2009.
April Harding Asia Network Private Health Sector Policy Bangkok Meeting February 1, 2010 Bali Hyatt Hotel, Sanur, Bali June 2010.
Workshop on Implementing Audit Quality Practices Working Group on Audit Manuals and Methods March 2006 Vilnius (Lithuania) Hungarian Experiences.
BUSINESS REGULATION AND CORPORATE CONDUCT (BRCC Project) Project Overview & Draft Thematic Research Report.
Policies and Procedures for Civil Society Participation in GEF Programme and Projects presented by GEF NGO Network ECW.
Raksha Sharda CUTS International 1 st National Reference Group (NRG) Meeting, India 24 th July,
NSDS DESIGN PROCESS: ROAD MAPS & OTHER PRELIMINARIES Prof. Ben Kiregyera NSDS Workshop, Addis Ababa, Ethiopia 9 August 2005.
12/5/2015 Communication on Progress Elena Panova UN Global Compact Network Bulgaria.
Private Health Sector Assessments (PHSA) April Harding 2011.
7-Up MARK II Methodology (Survey Component) for Country Report.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
The implementation programme for the 2008 SNA and supporting statistics UNECE special session on National Accounts for economies in transition Geneva,
Interplay between business relations and corporate conduct in H.P. An update on Pharmaceuticals and Private Healthcare sectors Study by Gunjan Organisation.
United Nations Oslo City Group on Energy Statistics OG7, Helsinki, Finland October 2012 ESCM Chapter 8: Data Quality and Meta Data 1.
Rethinking a Responsibility In India: a review of Pharmaceutical & Private Healthcare sectors BUSINESSES’ CONTRIBUTION TOWARDS GROWTH & SUSTAINABLE DEVELOPMENT.
Technology Needs Assessments under GEF Enabling Activities “Top Ups” UNFCCC/UNDP Expert Meeting on Methodologies for Technology Needs Assessments
COMPANY PROFILE  Corporate profile:   etc.  Mission and activities:   etc. 1/2.
27/04/2017 Strengthening of the Monitoring and Evaluation system for FTPP/FTTP in FAO /SEC December 2015 FTPP/FTFP Workshop, Bishkek, Kyrgyzstan.
Presentation to the 2004 ICAI Practice Conference Great Southern Hotel, Killarney 1 April, 2004 Ian Drennan Corporate Compliance Manager.
Business Responsibility in India: An Overview IDENTIFYING ELEMENTS OF BUSINESS RESPONSIBILITY IN PRIVATE HEALTHCARE IN INDIA (TRAINING WORKSHOP FOR PRIVATE.
MOROCCAN EXPERIENCE ON DISABILITY STATISTICS THE KINGDOM OF MOROCCO HIGH COMMISSION OF PLANNING BY ZINEB EL OUAZZANI TOUAHAMI Statistician Engineer Directorate.
5. Presentación general de la iniciativa REDD+ SES 5. Presentation of the REDD+ SES Initiative.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
ITC-ILO/ACTRAV Course A Trade Union Training on Occupational Safety, Health & HIV/AIDS (26/11 – 07/12/2012, Turin) Introduction to National Occupational.
Can Business Regulation Stimulate Responsible Corporate Conduct – Gathering Evidence from a Few Indian States RESEARCH METHODOLOGY BRCC Regional Dialogue.
Market Research Process
Rational Use of ARV Medicines
MANCOSA Honours Marketing Research.
Presented by Richard Laing
Adherence, attitude to Standard Treatment Guidelines in clinical practice at tertiary care hospitals in Delhi State 1Sangeeta Sharma, 2Sharma KK, 3Sethi.
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Presentation transcript:

EXPLORING THE INTERPLAY BETWEEN BUSINESS REGULATION & CORPORATE CONDUCT (BRCC) Rijit Sengupta Jaipur, 13 th April 2012

1. INTRODUCTION TO RESEARCH METHODOLOGY BRCC Research

Research Outline (BRCC Project)  Definition of Corporate Conduct – National Voluntary Guidelines on Social, Environmental & Economic Responsibilities of Business (NVG)  NVG: 9 Principles of Business Responsibility (BR)  Sectors: Pharmaceuticals and Private Healthcare  Value-Chain approach (Sectors) – critical BR issues  Identification of Research Problems 3

Research Problems (BRCC Project)  What is the level of adverse environmental impact (especially in terms of pollution) from Pharmaceutical companies in the state? Why have the available regulatory safeguards not worked in places where impacts were found to be significant? What should be done to make these regulations work, so that such adverse environmental impacts may be minimised?  What is the current status of incentives (cuts/commissions) provided by Pharmaceutical companies to Doctors and Chemists in the state? What impact does it have on ‘Rational Use of Drugs’? Why have these incentives continued to be provided by the companies, in spite of regulatory safeguards being in place? What can be done to ensure that companies undertake their marketing activities keeping in view the principle of ‘Rational Use of Drugs’? 4

Research Problems (BRCC Project)  How prevalent is the act of cuts/commissions to doctors (individuals/in hospitals) among diagnostic service providers in the state? Why have these cuts/commissions to doctors existed in spite of regulatory safeguards in place? How to combat the situation? What have been the efforts of hospital associations and other such collectives to deal with the problem? What are the regulatory barriers, if any?  What is the current status of bio-medical waste management practices being followed by hospitals and diagnostic service providers in the state? If the situation is problematic, why is it so – in spite of regulatory safeguards? How can the situation be corrected? What have been the steps taken up by the hospital associations/industry bodies to deal with the problem? What are the good practices? What are the drivers of good practices and how can these be scaled up or replicated? 5

Research Problems (BRCC Project)  What is the extent to which standard treatment protocol is being followed in the state by (private) healthcare providers? If there are deviations, what are the reasons for these and other instances of non-compliance? How can it be ensured that hospitals promote alignment with standard treatment protocol? Are there adequate measures undertaken by the healthcare providers to respect the diagnosis and treatment related queries of clients (patients and their attendants etc.)? Are there any self-regulatory mechanisms in place? 6

Field-work in States  Fact Finding Mission in States (Meeting Stakeholders, Ground Truth Verification, Initial Contacts, Data Sources, etc.)  Key Research Output  Guidance Note  Targeted Respondents  Survey Method and Tools  Draft State-level reports RegulationEnforcement Outcome (Corporate Conduct) Critical Factors 7

Targeted SHs Vs Survey Tools 8  INTERVIEWS: Government Deptt, Regulators, Business Associations, Sectoral Associations, Stakeholders (CSO/Academia, Media)  SAMPLE SURVEY: Pharma Firms, Private Hospitals, Medical Representatives  PRESCRIPTION ANALYSIS: Behaviour of doctors in Private Hospitals  FGDs: Medical Representatives, Media

2. ITEMS & APPROACH BRCC Field-work (States)

Approach to Undertaking Field-work  Stage-wise fieldwork: Stages I to III  Partners Workshop I: mid-April 2012 for Stage I  Partners Workshop II: end-May 2012 for Stages II & III  Survey Tools and Methodology: CUTS & Partners  State-level Reports: ToR by CUTS and guidance; drafting by partners; review by CUTS & Advisors  Approaching respondents for interviews in State: CUTS and Partners  Meeting and feedback from national level experts: CUTS 10

3. SURVEY OF PHARMA FIRMS BRCC Field-work (States)

Approach to Sample Selection in States PHARMACEUTICALS  Selection of districts in each state with maximum concentration of Pharma Firms  Total no. of firms in the selected districts, including distribution (i.e., no of Bulk and Formulations)  10% of total to be selected  Proportion of Bulk & Formulations same as their distribution in these districts  Large and SMEs to be selected 12

Questionnaire 13 Some element of flexibility to align questionnaires better to state is allowed (to be communicated to CUTS) Pre-Testing of questionnaire in States (partners) Set up the meeting by writing to the Firm Indicate the purpose is for research and policy advocacy Facilitate more comprehensive approach to BR Administer the questionnaire by giving opportunity to respondent to speak as much Gather both quantitative & qualitative info Undertake analysis with guidance from CUTS

14 Thank You!